SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

HSBCs bearish view on CoreWeave has amplified concerns about its debt-heavy data-center expansion, rising financing costs, and potentially slowing AI demand. Traders are split between buying the selloff and anticipating a short squeeze, and warning that credit and insider-selling risks could prolong the decline.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to elevated crude prices and fears that Middle East shipping or energy-infrastructure attacks could disrupt supply, while weighing possible diplomacy and Russian supply relief. The community is split between bulls focused on geopolitical risk and bears expecting the risk premium to fade, with some also warning that contract-roll effects and an extended run may amplify volatility.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is drawing attention after breaking to a new high, with traders linking the rally to European regulatory backing for its Foundayo obesity pill and broader optimism about its GLP-1 business. Bulls are celebrating the breakout and healthcares defensive appeal, while skeptics point to possible profit-taking, competition from Novo and the upcoming earnings report.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is being tied by traders to weakening confidence in Trump and the approaching midterms, alongside concerns about the companys limited business fundamentals and Truth Social. The discussion is broadly bearish, though some traders view the decline as a possible short-term trading bounce.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rebound toward a one-year high and the $30 level is driving discussion, with traders focused on whether the move can break through resistance. Some see momentum from a defensive-sector rotation and pipeline developments ahead of earnings, while others say the stock needs stronger news to sustain a breakout.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention for a sharp rebound after a tech-led selloff, which traders link to unconfirmed reports of potential U.S.-Iran talks and easing oil prices. The community is split between viewing the move as a bullish reversal and warning it may be a bull trap amid persistent volatility and concerns about tech and AI stocks.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential but also to concerns about modest symptom improvement, agitation-related side effects, and discontinuations. Traders are divided, with some viewing the move as a fading bounce and adding shorts while others point to bullish analyst commentary.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a sharp neocloud and AI-infrastructure selloff as traders weigh Gartners warning about the sectors economics and broader concerns over debt, funding, and project execution. The community is split between expecting further declines and buying an oversold dip; some cite the CEOs assurances about data-center financing, while others point to Horizon 2 delays and weak price action.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after strong Q3 results and an upbeat outlook, with AI-related demand and growing Vertical Power Delivery royalty revenue reinforcing the growth story. Traders are weighing that strength against questions about one-time royalty catch-up payments, production capacity, and the earnings-per-share miss, contributing to a volatile reaction.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly results beat expectations and the company raised its outlook, but shares fell as traders weighed rising costs, weaker cash flow and a loss in its insurance business. The reaction has split the community between buyers calling the selloff unjustified after a strong report and bears focused on the cost pressures and weak price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BETA BIONICS, INC. (NASDAQ: BBNX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by November 3, 2026

BETA BIONICS, INC. (NASDAQ: BBNX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by November 3, 2026 BETA BIONICS, INC. (NASDAQ: BBNX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a...

BBNX 2-WEEK DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens Berman

BBNX 2-WEEK DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens Berman BBNX 2-WEEK DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens BermanPR NewswireSAN FRANCISCO, Oct. 20...

Investor Alert: Beta Bionics (BBNX) has been Sued for Securities Fraud Over Alleged Misstatements made to Investors

Investor Alert: Beta Bionics (BBNX) has been Sued for Securities Fraud Over Alleged Misstatements made to Investors Investor Alert: Beta Bionics (BBNX) has been Sued for Securities Fraud Over Alleged Misstatements made to InvestorsPR NewswireNEW YORK, Oct. 20, 2026 A securities fraud class action...

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Beta Bionics, Inc. to Contact Law Firm

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Beta Bionics, Inc. to Contact Law Firm INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Beta Bionics, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 19, 2026 Beta Bionics, Inc. (NASDAQ: BBNX) shareholders should email...

Robbins LLP Reminds BBNX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Seeking Lead Plaintiff Status

Robbins LLP Reminds BBNX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Seeking Lead Plaintiff Status Robbins LLP Reminds BBNX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About...

Beta Bionics (BBNX) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline

Beta Bionics (BBNX) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline Beta Bionics (BBNX) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 3...

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNXPR NewswireNEW YORK, Oct. 15, 2026The lawsuit contends Beta...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BBNX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BBNX INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and...

Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - BBNX

Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - BBNX Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - BBNXPR...

BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit

BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces...

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Beta Bionics Inc.

Beta Bionics Stock Gains After Mixed Analyst Coverage; Wolfe Bullish, Goldman Neutral

Equity

Bearish Sentiment

Shares of Beta Bionics rose Thursday following the initiation of coverage by two Wall Street financial firms on the diabetes-focused medical technology company.Beta Bionics shares climbed 6.4% to close at $15.36 on Thursday, with an additional 0.8% gain in after-hours trading.Goldman Sachs assigned Beta Bionics a ‘Neutral’ rating with a $16 price target, as its technology targets a specific portion of the Type 1 diabetes market.&nbsp;Still, current consensus expectations already account for most of its immediate growth possibilities.&nbsp;According to analyst David Roman, Beta Bionics' current valuation reflects two key factors: its projected growth positions it to outperform diabetes peers and SMID-cap medtech firms in the near term.At the same time, the valuation also prices in the expected need for capital raises to reach cash flow breakeven.Meanwhile, Wolfe Research signaled optimism&nbsp;by initiating coverage with an ‘Outperform’ rating and a $20 price target.Beta Bionics created the iLet Bionic Pancreas device, which automates insulin delivery for individuals with Type 1 diabetes.Recently, the medical technology firm posted strong Q1 2025 results, with net sales growth of 36% year over year, bringing total sales to $17.6 million.&nbsp;The company saw growth through a 360% increase in Pharmacy Benefit Plan (PBP) channel sales and a 291% rise in the installed user base, reaching over 19,000.&nbsp;Operating losses rose to $18.6 million, resulting in a net loss of $28.7 million.Beta Bionics projects FY25 revenues between $82 and $87 million and gross margins between 50% and 53% while expecting a rise in new patient starts through the PBP channel.On Stocktwits, retail sentiment was ‘neutral’ amid ‘low’ message volume.Beta Bionics stock has declined 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, logos of Beta Bionics are displayed on mobile phone screen and computer screen in Ankara, Turkiye on September 5, 2023. (Photo by Arda Kucukkaya/Anadolu Agency via Getty Images)

Wolfe Research initiated coverage with an ‘Outperform’ rating and a $20 target, while Goldman Sachs started at ‘Neutral’ with a $16 target, citing balanced growth prospects and valuation.

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

$BBNX Hi Beta Bionics shareholders 

Any new details about the dual-hormone pump progress?

I believe that would be the day you make it big, as the only option offering both glucagon and insulin in one device in the entire industry. That would be a segment-redefining moment, transitioning from AID (Automated Insulin Delivery) to AGID (Automated Glucagon and Insulin Delivery). 

Glta 🖖

Alon Rosenzweig

$BBNX 
 
Two 28-dollar targets in two days: Wells Fargo initiated at Overweight with a 28 target on Wednesday, and Truist lifted to 28 from 23 on Thursday, keeping its Buy (per Dow Jones). 
 
The stock is coming back from a January washout. It dropped 37 percent over two days early in the year after disclosing FDA compliance and device-safety issues around the iLet insulin pump. A class action now alleges the company failed to disclose a June 2025 Form 483 and more than 18,000 iLet complaints (lead-plaintiff deadline November 3). 
 
The tape has quietly recovered: from an 8.80 low to 21.51 Friday, with 8 buys, 4 holds and 1 sell and an average target of 22.91 (MarketBeat). 
 
Wells and Truist are saying that washout was the bottom.

Krypton Research

$BBNX longer time frames will look ugly, but I like the r/r here. Found on runner + 10% pullback scanu

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBNX Beta Bionics Inc.

Fundamentals

Latest BBNX News